Outcomes Of Percutaneous Coronary Intervention In Patients Research Articles

Long Term Outcome of Percutaneous Coronary Intervention in Patients with Unprotected Left Main Disease

Background: The management of unprotected left main coronary artery disease (LM CAD) poses a significant clinical challenge. Percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) have been extensively compared, with PCI emerging as a viable option for specific patient subsets. Advancements in interventional cardiology, including drug-eluting stents and intravascular ultrasound, have improved PCI outcomes, yet long-term efficacy remains a subject of investigation. Objective: This study aims to evaluate the long-term outcomes of PCI in patients with unprotected LM CAD, focusing on all-cause mortality, cardiac deaths, myocardial infarction, revascularization, and stroke. Methods: A descriptive cross-sectional study was conducted at the Peshawar Institute of Cardiology, KPK, from November 2022 to October 2023. A total of 120 patients aged 55-70 years with LM disease undergoing PCI were included. Long-term outcomes were assessed after five years. Data analysis was performed using SPSS version 23, focusing on frequency and association of outcomes with gender. Results: The study observed all-cause mortality in 15.0% (n=18) of the patients, cardiovascular mortality in 6.7% (n=8), myocardial infarction in 7.5% (n=9), revascularization in 14.2% (n=17), and stroke in 4.2% (n=5). Gender analysis revealed no significant difference in all-cause mortality (P=0.73), with a notable gender disparity in cardiovascular mortality favoring females (P=0.04). Revascularization and stroke rates did not significantly differ by gender. Conclusion: PCI presents a favorable and safe long-term treatment option for patients with unprotected LM CAD, with significant outcomes in terms of mortality, myocardial infarction, revascularization, and stroke. The study supports the continued use of PCI in clinical practice, highlighting the necessity for further comparative research with CABG to optimize patient outcomes.

Chronic Myeloid Leukemia and Myocardial Infarction: A Nationwide Readmission Database Analysis

Introduction Chronic myeloid leukemia (CML) is a hematological malignancy with an excellent outcome. After advancements in CML treatment and the introduction of different Tyrosine kinase inhibitors (TKI), their life expectancy is equivalent to the normal population. As a result of that, coronary artery disease is anticipated to be the leading cause of death among CML patients. It was particularly noted that TKI use is associated with the risk of endothelial dysfunction and it associated risk of cardiovascular events, including myocardial infarction. In this study, we compare the outcome of PCI in patients with CML to their matched non-CML group. Method The National readmission database (NRD) was searched from January 2016 to December 2020 for the study population. Adults above (age ≥ 18 years) with chronic myeloid leukemia hospitalized with a primary diagnosis of myocardial infarction, ST Elevation Myocardial Infarction (STEMI), and Non-ST-elevation myocardial infarction (NSTEMI) were identified using ICD 10 code. The primary outcomes were in-hospital mortality and 30-day readmission, and the secondary outcome was to compare the complications. The weighting of patient-level observations was implemented to obtain national estimates. Multivariate regression analysis models were built by including all confounders significantly associated with the outcome on univariable analysis with a cutoff P-value of 0.2. Variables deemed important determinants of the outcomes based on literature were forced into the models. For readmission comparison, we used the time-to-event Cox regression analysis. Propensity matching was done by the Greedy method. Proportions were compared using the Mantel-Haenszel Chi-square test or Fisher exact test, and continuous variables were compared using the Student t-test. All P values were two-sided, with .05 as the threshold for statistical significance. Results Out of 2727619 patients with myocardial infarction, 2124 CML patients were identified, and 888 CML patients had Percutaneous Coronary Intervention (PCI). Patients' baseline characteristics and major outcomes were compared (table 1). The mean age of CML patients was 68.34 ± 11.14 (P<0.001). The analysis showed no significant difference between CML and non-CML patients after PCI for the primary outcome of death 0.93 (CI 0.49-1.80) P value 0.527 and 30 days readmission rate 1.41 (0.99-2.01) P value 0.056. Also, there was no statistical significance in developing major complications, including cardiac arrest, coronary artery dissection, cardiac tamponade, stroke, thrombosis, major bleeding, AKI, and dialysis. Discussion and Conclusion Patients with hematologic malignancies, including chronic myeloid leukemia, are at increased risk of thrombosis. In CML, thrombosis can be venous or arterial (myocardial infarction, cerebrovascular accidents, and peripheral artery disease). Arterial thrombosis in CML is primarily linked to using different TKIs, and thrombotic events were reported with the second-generation TKIs like nilotinib, dasatinib, and ponatinib more often than with first-generation TKIs. The mechanism of TKI use-associated thrombosis is likely related to TKI-associated endothelial dysfunction and vascular toxicity that lead to accelerated atherosclerosis and subsequent vascular thrombosis. This increased risk might lead to an assumption of an increased risk of complications with vascular intervention like PCI. Some studies showed that PCI for hematological cancer patients with STEMI have no significant difference regarding in-hospital mortality. This analysis of patients with CML with myocardial infarction ( STEMI and NSTEMI ) showed no statistically significant difference in outcome after PCI between the two groups. There were no significant differences in mortality, 30 days readmission rate, and other complications post PCI. Therefore, diagnosis of chronic myeloid leukemia shouldn't prevent patients from receiving routine therapy and intervention because of the theoretical risk of thrombosis. This information aid in patient counseling and achieving the objective of maintaining a normal quality of life for chronic myeloid leukemia patients.

In-hospital outcomes of PCI in patients who have ESRD vs non-ESRD patients, a retrospective study involving a National Inpatient Sample (NIS) database

BackgroundCardiovascular disease is the leading cause of death for patients with end-stage renal disease (ESRD). ESRD is known to affect a large portion of the American population. Previous data for patients undergoing percutaneous coronary intervention (PCI) in the setting of ESRD for Acute Coronary Syndrome (ACS) and non-ACS etiologies have shown to have an increase in in-hospital mortality, and prolonged hospitalization among other complications. MethodsThe national inpatient sample (NIS) was used to identify patients who underwent PCI between the years 2016–2019. Patients were then grouped into those with ESRD on renal replacement therapy (RRT). Logistic regression models were employed to assess the primary outcome of in-hospital mortality, while linear regression models were utilized to evaluate secondary outcomes, including hospitalization cost and length of stay. ResultsA total of 21,366 unweighted observations were initially included, consisting of 50 % ESRD patients and 50 % randomly selected patients without ESRD who underwent PCI. These observations were weighted to represent a national estimate of 106,830 patients. The mean age of the study population was 65 years, and 63 % of the patients were male. The ESRD group had a greater representation of minority groups compared to the control group. The in-hospital mortality rate was significantly higher in the ESRD group compared to the control group, with an odds ratio of 1.803 (95 % CI: 1.502 to 2.164; p-value of 0.0002). Additionally, the ESRD group had significantly higher healthcare costs and longer length of stay, with a mean difference of $47,618 (95 % CI: $42,701 to $52,534, p-value <0.0001) and 2.933 days (95 % CI, 2.729 to 3.138 days, p-value <0.0001), respectively. ConclusionIn-hospital mortality, cost, and length of stay for patients undergoing PCI were found to be significantly greater in the ESRD group.

Outcomes of Prediabetes Compared with Normoglycaemia and Diabetes Mellitus in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis.

Background: Patients with prediabetes are at increased risk of coronary artery disease (CAD). However, the association between prediabetes and adverse clinical outcomes following percutaneous coronary intervention (PCI) is inconsistent, in contrast to outcomes in patients with diabetes mellitus (DM). Thus, this meta-analysis evaluated the impact of dysglycaemia on PCI outcomes. Methods: The PubMed, Embase, Cochrane, and ClinicalTrials.gov databases were systematically reviewed from inception of databases until June 2022. In 17 studies, outcomes of PCI in patients with prediabetes were compared with patients who were normoglycaemic, and patients with DM. The primary outcome was all-cause mortality at the longest follow-up. Results: Included were 12 prospective and five retrospective studies, with 11,868, 14,894 and 13,536 patients undergoing PCI in the prediabetes, normoglycaemic and DM groups, respectively. Normoglycaemic patients had a statistically lower risk of all-cause mortality, (risk ratio [RR] 0.66, 95% confidence interval [CI] 0.52-0.84), myocardial infarction (MI; RR 0.76, 95% CI 0.61-0.95) and cardiac mortality (RR 0.58, 95% CI 0.39-0.87) compared with prediabetic patients undergoing PCI at the longest follow-up. Patients with prediabetes had a lower risk of all-cause mortality (RR=0.72 [95% CI 0.53-0.97]) and cardiac mortality (RR =0.47 [95% CI 0.23-0.93]) compared with patients with DM who underwent PCI. Conclusion: Among patients who underwent PCI for CAD, the risk of all-cause and cardiac mortality, major adverse cardiovascular events and MI in prediabetic patients was higher compared with normoglycaemic patients but lower compared with patients with DM.

Abstract 13197: Increased Cardiac and All-Cause Mortality After Percutaneous Coronary Intervention in Subclinical Hypothyroidism: A Meta-Analysis

Background: Subclinical hypothyroidism (elevated TSH with normal thyroid hormone levels), is associated with an increased risk of cardiovascular diseases like atherosclerosis and coronary artery disease. However, its impact on long-term outcomes after percutaneous coronary intervention (PCI) remains understudied. Methods: PubMed, EMBASE, and Web of Science databases were screened through June 2021 for studies reporting long-term PCI outcomes in patients with subclinical hypothyroid state vs. Euthyroid state. Random effects models were used for the meta-analysis. I2 statistics were used to interpret heterogeneity with I 2 &gt;75% indicating substantial inter-study variation. A sensitivity analysis was performed using the leave one out method. A p-value &lt;0.05 was considered statistically significant. Results: A total of 6 studies including 11,664 patients who had undergone PCI were identified with a median follow-up period of 3.75 years. There were 987 patients identified with subclinical hypothyroidism and the mean age of the cohort was 67.15 ± 9.9 years. It consisted of 48% males, the most common comorbidities were hypertension (70%) followed by diabetes mellitus (33%). In-hospital outcomes were reported only in one study while long-term outcomes were reported in all 6 studies. Pooled analysis for long-term adverse events showed that subclinical hypothyroidism was associated with increased all-cause (OR 1.78, 95%CI: 1.16-2.72, p&lt;0.01, I 2 =50.67%) and cardiac mortality (OR 1.41, 95%CI: 1.09=1.81, p&lt;0.01, I 2 =0%) over long-term follow-up following PCI Conclusions: Subclinical hypothyroidism at times remains undiagnosed or underdiagnosed, however, it predicts significantly higher all-cause and cardiac mortality in the long term following PCI compared to controls. Therefore, it is recommended to regularly screen and manage high-risk patients undergoing PCI with underlying subclinical hypothyroidism.

OUTCOMES OF CHRONIC TOTAL OCCLUSION PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH PRIOR CORONARY ARTERY BYPASS GRAFT SURGERY

Chronic total occlusion (CTO) percutaneous coronary intervention (PCI) in patients with prior bypass surgery (CABG) can be challenging. We conducted a meta-analysis of studies that compared the in-hospital outcomes of CTO PCI in patients with vs. without prior CABG published until August 2019.

Impact Of Cirrhosis On 90-Day Outcomes After Percutaneous Coronary Intervention (from A Nationwide Database)

Patients with cirrhosis often have concomitant coronary artery disease and require percutaneous coronary intervention (PCI). PCI in cirrhotics can be associated with significant risks due to thrombocytopenia, possible coagulopathies, bleeding, and renal failure. Longer term risks of PCI in cirrhotics have not been well studied. Our study seeks to evaluate the 90-day outcomes of PCI in patients with cirrhosis. Patients receiving PCI were identified from the Nationwide Readmissions Database from 2010 to 2014 and stratified by the presence of co-morbid cirrhosis. The total mortality during index admission and 90-day readmissions as well as the readmissions rate were examined. Adverse events including bleeding, stroke, kidney injury, and vascular complications were also compared. Patients with cirrhosis had a significantly higher number of co-morbidities. The cirrhosis group had a higher overall 90-day mortality (10.3% vs 2.5%, p < 0.01), including during the index hospitalization (7.0% vs 1.8%, p < 0.01), as well as a higher 90-day readmission rate (38.2% vs 20.2%, p < 0.01). Patients with cirrhosis also had higher frequencies of overall 90-day adverse events (44.7% vs 17.7%, p < 0.01), including gastrointestinal bleeding (15.3% vs 2.7%, p < 0.01) and acute kidney injury (28.4% vs 10.1%, p < 0.01). In conclusion, patients with cirrhosis face a significantly higher risk of adverse outcomes including mortality, readmissions, and adverse events in the 90 days after hospitalization for PCI compared with the general population.

TCT-294 Long Term Outcome of Unprotected Left Main Coronary Artery Disease: Comparison between Coronary Artery Bypass Grafting (CABG) and Percutaneous Coronary Intervention (PCI) in Korean Single Center

The benefit of CABG over PCI for the patients with ULMCAD is controversial. Although many studies had less favorable short and mid-term outcomes of PCI in patients compare to CABG, there were limited papers on the long term survival outcomes. We sought to compare the long term (10 years) outcomes of

Australian Trends in Procedural Characteristics and Outcomes in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction

Over the last decade, systems of care for ST-elevation myocardial infarction (STEMI) have evolved to try to improve outcomes and timely access to percutaneous coronary intervention (PCI). There have also been advances in PCI techniques and adjunctive pharmacotherapies. In this study, we sought to determine temporal changes in practices and clinical outcomes of PCI in patients with STEMI. We prospectively collected data on 8,412 consecutive patients undergoing PCI for STEMI between 2005 and 2016 in the multicenter Melbourne Interventional Group registry. Data were divided by procedure year for trends analysis. The primary end point was 30-day mortality. Patient demographics and comorbidities including smoking and diabetes have remained stable. The volume of primary PCI performed within 12 hours of symptom onset has significantly risen (65.7% to 80.1%, p < 0.01). The proportion of patients achieving the recommended door-to-balloon time ≤90 minutes has also risen (37.6% to 59.0%, p < 0.01). Patient complexity has also increased with more patients after out-of-hospital cardiac arrest with STEMI now being treated with PCI (2.6% to 9.1%, p < 0.01). A shift from mainly femoral to radial access and from bare-metal to drug-eluting stent use was seen. Glycoprotein IIb/IIIa inhibitors are being used less frequently with increasing use of newer antiplatelet agents. Thirty-day mortality has remained low throughout the study period at 6.5% overall. In conclusion, although timely access to primary PCI has improved, mortality rates have remained unchanged, but remain low and compare favorably with international data. Australian PCI practice has overall evolved in response to evidence and emergence of new adjunctive device and pharmacotherapies.

Percutaneous Coronary Intervention of Chronic Total Occlusions in Patients With Low Left Ventricular Ejection Fraction

ObjectivesThe study sought to assess the outcome of percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) in patients with low left ventricular ejection fraction (LVEF) (≤35%). BackgroundData regarding the outcome of PCI in patients with low LVEF affected by CTO are scarcely reported. MethodsThe authors performed a prospective longitudinal multicenter study including consecutive patients undergoing elective PCI of CTOs. Patients were subdivided into 3 groups: group 1 (LVEF ≥50%), group 2 (LVEF 35% to 50%), and group 3 (LVEF ≤35%). ResultsA total of 839 patients (mean 64.6 ± 10.5 years of age, 87.7% men) underwent CTO PCI attempts. Baseline LVEF ≤35% was present in 72 (8.6%) patients. The angiographic success was high (overall 93.6%) and similar among the 3 groups (93.5% vs. 94.4% vs. 91.7%, respectively; all p = NS). In group 3, no periprocedural complications of CTO PCI were observed. Mean clinical follow-up of 16.3 ± 8.2 months duration was available in 781 (93.1%) patients including those with LVEF ≤35%. At 2 years, major cardiac and cerebrovascular events (MACCE) free survival was similar in the 3 groups (86% vs. 82.8% vs. 75.2%; all p = NS). In patients with LVEF ≤35%, LVEF improved significantly in the presence of a successful CTO PCI from 29.1 ± 3.4% to 41.6 ± 7.9% (p < 0.001). ConclusionsIn CTO patients with low LVEF, PCI could represent a safe and effective revascularization strategy achieving good midterm outcome and LVEF improvement.

Comparable Periprocedural Outcomes of Percutaneous Coronary Intervention in Male and Female Patients with Type C Lesions

Background Percutaneous coronary intervention (PCI) in type C lesions has low success and has high procedural risk. We aimed at studying the outcomes of PCI in patients with type C lesions. Material and Methods Total 180 patients with type C lesions who underwent PCI from January 2007 to December 2014 were taken into study and analyzed. Results Of 180 patients, 141(78.3%) were males and 39 (21.7%) were females. Mean hemoglobin concentration, mean serum triglycerides, and mean estimated glomerular filtration rate were significantly lower in females compared with males. Seventy-seven (42.8%) patients had lesions in right coronary artery, 67 (37.2%) had lesions in left anterior descending coronary artery, 31 (17.2%) had lesions in left circumflex artery, and 5 (2.8%) had left main coronary artery disease. Complex lesions were common in males. Chronic total occlusion (CTO) was found in 140 cases and other than CTO of type C lesions in 40 patients. Predilatation was done in 169 (93.9%) patients. Successful PCI was done in 157 (87.2%) patients. Lesion could not be crossed in 11 (6.1%) patients. Only plain old balloon angioplasty could be done in 9 (5%) patients. Other complications occurred in 3 (1.67%) patients. There was no difference between female and male patients in requiring predilatation or crossing the lesion or in not being able to deliver the stent. Conclusion PCI success rate among patients with type C lesions was 87.2% with low-complication rate in the present era. There was no difference in between female and male patients in success rate or complications.

Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction: A Report From the CathPCI Registry.

The purpose of this study was to examine the temporal trends in demographics, clinical characteristics, management strategies, and in-hospital outcomes in patients with acute myocardial infarction complicated by cardiogenic shock (CS-AMI) who underwent percutaneous coronary intervention (PCI) from the Cath-PCI Registry (2005 to 2013). The authors examined contemporary use and outcomes of PCI in patients with CS-AMI. The authors used the Cath-PCI Registry to evaluate 56,497 patients (January 2005 to December 2013) undergoing PCI for CS-AMI. Temporal trends in clinical variables and outcomes were assessed. Compared with cases performed from 2005 to 2006, CS-AMI patients receiving PCI from 2011 to 2013 were more likely to have diabetes, hypertension, dyslipidemia, previous PCI, dialysis, but less likely to have chronic lung disease, peripheral vascular disease, or heart failure within 2 weeks (p < 0.01). Between 2005 and 2006 to 2011 and 2013, intra-aortic balloon pump use decreased (49.5% to 44.9%; p < 0.01), drug-eluting stent use declined (65% to 46%; p < 0.01), and the use of bivalirudin increased (12.6% to 45.6%). Adjusted in-hospital mortality; increased (27.6% in 2005 to 2006 vs. 30.6% in 2011 to 2013, adjusted odds ratio: 1.09, 95% confidence interval: 1.005 to .173; p = 0.04) for patients who were managed with an early invasive strategy (<24 h from symptoms). Our study shows that despite the evolution of medical technology and use of contemporary therapeutic measures, in-hospital mortality in CS-AMI patients who are managed invasively continues to rise. Additional research and targeted efforts are indicated to improve outcomes in this high-risk cohort.

Effect of intensive statin therapy on coronary intervention outcomes, cardiac markers, vaspin, and adiponectin levels in elderly patients with coronary heart disease

Aim: To explore the effect of intensive statin therapy (different doses) on percutaneous coronary intervention (PCI) outcomes in elderly patients with coronary heart disease (CHD). Methods: In this Institutional Ethics Committee-approved study, 105 elderly patients (> 80-year-old) with CHD admitted into the First Affiliated Hospital of Jinan University from June 2012 to June 2014 were randomly divided into three groups and received 20 mg/day, 40 mg/day, or 60 mg/day atorvastatin, respectively, before PCI surgery. Postsurgical (1 month after surgery) changes in major adverse cardiovascular events (MACEs), cardiac markers, vaspin, and adiponectin levels were compared among the groups. Results: Among the study groups, the incidence of MACE and PCI-related myocardial infarction rate was the lowest in 60 mg group (2.9%) reaching significance ( P P P P P > 0.05). No study subjects showed statin-related myopathy. Conclusion: The application of 60 mg/d intensive statin therapy in short term could improve outcomes of PCI in patients with elderly CHD, maintain stable levels of cardiac markers, Vaspin and adiponectin, with exact effect and good safety.

Impact of prior statin use on percutaneous coronary intervention outcomes in acute coronary syndrome

BackgroundThe use of statins prior to percutaneous coronary intervention (PCI) has reduced cardiac events in both short and long-term follow-up. This study assessed the impact of prior statin use on in-hospital PCI outcomes in patients with acute coronary syndrome (ACS). MethodsRetrospective analysis of a multicenter registry of 6,288 consecutive patients undergoing PCI. Of these, 35% had ACS and were evaluated according to statin use (Group 1, n=1,203) or no use (Group 2, n=999). ResultsGroup 1 showed higher prevalence of dyslipidemia, acute myocardial infarction (AMI), previous coronary artery bypass graft, chronic renal failure, multivessel involvement, bifurcation lesions, and use of drug-eluting stents. Group 2 showed more primary and rescue PCIs, Killip functional class III/IV, B2/C lesions, thrombi, total occlusions, pre-procedural TIMI 0/1 flow, presence of collateral circulation, and use of glycoprotein IIb/IIIa inhibitors and aspiration catheters. PCI success was higher in Group 1 (95.1% vs. 92.5%; p=0.01), and the occurrence of major adverse cerebrovascular and cardiac events (MACCE) (3.7% vs. 5.7%) was more frequent in Group 2. Although the non-use of statins showed an association with MACCE in the univariate analysis, independent predictors of in-hospital MACCE were limited to AMI in Killip III/IV and prior coronary artery bypass graft. ConclusionsACS patients undergoing PCI who previously used statins had better in-hospital clinical outcomes; however, statin use was not an independent predictor of MACCE.

Impacto do uso prévio de estatinas nos resultados da intervenção coronária percutânea na síndrome coronariana aguda

BackgroundThe use of statins prior to percutaneous coronary intervention (PCI) has reduced cardiac events in both short and long‐term follow‐up. This study assessed the impact of prior statin use on in‐hospital PCI outcomes in patients with acute coronary syndrome (ACS). MethodsRetrospective analysis of a multicenter registry of 6,288 consecutive patients undergoing PCI. Of these, 35% had ACS and were evaluated according to statin use (Group 1, n = 1,203) or no use (Group 2, n = 999). ResultsGroup 1 showed higher prevalence of dyslipidemia, acute myocardial infarction (AMI), previous coronary artery bypass graft, chronic renal failure, multivessel involvement, bifurcation lesions, and use of drug‐eluting stents. Group 2 showed more primary and rescue PCIs, Killip functional class III/IV, B2/C lesions, thrombi, total occlusions, pre‐procedural TIMI 0/1 flow, presence of collateral circulation, and use of glycoprotein IIb/IIIa inhibitors and aspiration catheters. PCI success was higher in Group 1 (95.1% vs. 92.5%; p = 0.01), and the occurrence of major adverse cerebrovascular and cardiac events (MACCE) (3.7% vs. 5.7%) was more frequent in Group 2. Although the non‐use of statins showed an association with MACCE in the univariate analysis, independent predictors of in‐hospital MACCE were limited to AMI in Killip III/IV and prior coronary artery bypass graft. ConclusionsACS patients undergoing PCI who previously used statins had better in‐hospital clinical outcomes; however, statin use was not an independent predictor of MACCE.

Percutaneous Coronary Intervention (PCI) of Chronic Total Occlusion (CTO) lesion in Bangladeshi patient population: a single center experience- In hospital and 90 days outcome

Objectives Aim of the study was to evaluate the primary in-hospital success and 90 days outcome of PCI in patients with CTO lesions, using either Bare-metal stents (BMS) or Drug Eluting Stent (DES) like Sirolimus-eluting or Paclitaxel-eluting stent. Methods Total 71 patients were included in this non-randomized prospective cohort as per the definition of CTO, from a total of 875 patients who had PCI at our center in the quantifying period. Total 92 stents were deployed in 71 patients. After the guide wire crossing and the balloon dilation, measurement of the culprit lesion were done by using Siemens QCA measuring system. Among the patients, Male: 59 and Female: 12. Mean age were for Male: 53yrs, for Female: 65yrs. Associated CAD risk factors were Dyslipidemia, High Blood pressure, Diabetes Mellitus, Positive FH for CAD and Smoking (all male). Results Our study shows 71 patients (8.1%) had CTO lesion out of total 875 PCI procedures. Among the study group; 56 (79%) were Dyslipidemic, 50 (70%) were hypertensive: 40 (56%) patients were Diabetic, 25 (42%) were all male smoker. Female patients were more obese (BMI M 26: F 27) and developed CAD in advance age. We found that the incidences of CTO lesions were more in LAD territory 27 (38%) followed by RCA 26 (37%) and LCX 18 (25%). Average length and diameter of stented vessel was greater in RCA than LAD and LCX. Stents used: BMS 34 (36.9%), Sirolimus 25 (27.2%), Paclitaxel 18 (19.6%), Biolimus 10 (10.8%) and Everolimus 5 (5.4%). Post procedural, in-hospital and 90 days out come was 100% in our present study. Conclusion Our study has revealed that PCI in patients with CTO lesion has shown good success rate in our hospital with no procedural complication both in-hospital and 90 days after, either treated with BMS or DES. DOI: http://dx.doi.org/10.3329/pulse.v5i1.20185 Pulse Vol.5 January 2011 p.19-26

Recovery of left ventricular function after percutaneous revascularization of a left main chronic total occlusion

Surgical revascularization of left main and/or three-vessel coronary artery disease (CAD) is associated with improved survival in patients with left ventricular dysfunction when compared to medical therapy and can result in improved left ventricular ejection fraction (LVEF) [1]. Multivessel percutaneous coronary intervention (PCI) is equivalent to surgery regarding short and intermediate term mortality, and left main PCI has emerged as a safe and effective alternate to surgical revascularization [2]. However, outcomes of unprotected left main PCI in patients with severely depressed LVEF have not been examined. We report a patient with left main chronic total occlusion, multivessel CAD, and dilated cardiomyopathy, in whom complete revascularization via PCI resulted in decreased left ventricular size and improved LVEF.

AS-183 Percutaneous Coronary Intervention (PCI) of Chronic Total Occlusion (CTO) Lesion : Our Experience, In-hospital and 90-days Outcome

Primary Aim of the study was to evaluate the primary in-hospital success and 90-days outcome of PCI in patients with CTO lesions, using either Bare-metal stents (BMS) or Drug Eluting Stent (DES) like Sirolimus-eluting or Paclitaxel-eluting stent.

Percutaneous Coronary Intervention in Patients With Severe Aortic Stenosis

Background— With the availability of transcatheter aortic valve replacement, management of coronary artery disease in patients with severe aortic stenosis (AS) is posing challenges. Outcomes of percutaneous coronary intervention (PCI) in patients with severe AS and coronary artery disease remain unknown. We sought to compare the short-term outcomes of PCI in patients with and without AS. Methods and Results— From our PCI database, we identified 254 patients with severe AS who underwent PCI between 1998 and 2008. Using propensity matching, we found 508 patients without AS who underwent PCI in the same period. The primary end point of 30-day mortality after PCI was similar in patients with and without severe AS (4.3% [11 of 254] versus 4.7% [24 of 508]; hazard ratio, 0.93; 95% confidence interval, 0.51–1.69; P =0.2). Patients with low ejection fraction (≤30%) and severe AS had a higher 30-day post-PCI mortality compared with those with an ejection fraction &gt;30% (5.4% [7 of 45] versus 1.2% [4 of 209]; P &lt;0.001). In addition, AS patients with high Society of Thoracic Surgeons score (≥10) had a higher 30-day post-PCI mortality than those with a Society of Thoracic Surgeons score &lt;10 (10.4% [10 of 96] versus 0%; P &lt;0.001). Conclusions— PCI can be performed in patients with severe symptomatic AS and coronary artery disease without an increased risk of short-term mortality compared with propensity-matched patients without AS. Patients with ejection fraction ≤30% and Society of Thoracic Surgeons score ≥10% are at a highest risk of 30-day mortality after PCI. This finding has significant implications in the management of severe coronary artery disease in high-risk severe symptomatic AS patients being considered for transcatheter aortic valve replacement.

The prognostic value of pregnancy-associated plasma protein A for outcome of percutaneous coronary intervention in patients with non-ST-elevation acute coronary syndrome

ObjectiveTo investigate the relationship between the levels of circulating pregnancy-associated plasma protein A (PAPP-A), a novel marker of atherosclerotic plaque activity, and mid-term outcome of percutaneous coronary intervention (PCI) in...